McKinsey Confirms Pharma Forecasts Fragile; Can Industry Learn To Survive Without Them (Forecasts, That Is)?

Perhaps the most interesting implication here is that biopharma's success is likely to depend their ability to "pick the winners," and more upon their learning how to lose less painfully, and fail fast, cheap, and often.